Interaction Checker

Interaksi Lanreotid

Lanreotid (Somatuline Depot) memiliki 68 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 2 mayor, 66 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (2)

  • Dekstrometorfan dan kuinidinobat serotonergikMayor

    Since it cannot be excluded that Lanreotide Injection may have this effect, avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine). (label Lanreotid, Interaksi obat)

  • KuinidinantiaritmiaMayor

    Since it cannot be excluded that Lanreotide Injection may have this effect, avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine). (label Lanreotid, Interaksi obat)

Interaksi moderat (66)

  • AkarbosaantidiabetesModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Alogliptinpenghambat DPP-4Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Asebutololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Atenololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Atenolol dan klortalidonpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Beksagliflozinpenghambat SGLT2Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Betaksololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Bisoprololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Bisoprolol dan hidroklorotiazidpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Brimonidin dan timololagonis alfa-adrenergikModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Bromokriptinagonis dopaminModerat

    Bromocriptine : Lanreotide Injection may increase the absorption of bromocriptine. (label Lanreotid, Interaksi obat)

  • Dapagliflozinpenghambat SGLT2Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Dorzolamid dan timololpenghambat karbonat anhidraseModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Dulaglutidagonis reseptor GLP-1Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Eksenatidagonis reseptor GLP-1Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Empagliflozinpenghambat SGLT2Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Esmololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • GlibenklamidsulfonilureaModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Glibenklamid dan metforminsulfonilureaModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • GlimepiridsulfonilureaModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • GlipizidsulfonilureaModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Glipizid dan metforminsulfonilureaModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • GlukagonModerat

    Hyperglycemia and Hypoglycemia Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. (label Lanreotid, Peringatan dan perhatian)

  • Insulin aspartinsulinModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Insulin degludekinsulinModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Insulin detemirinsulinModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Insulin glargininsulinModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Insulin lisproinsulinModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Insulin reguler (manusia)insulinModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Kanagliflozinpenghambat SGLT2Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Labetalolpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Levotiroksinhormon tiroidModerat

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (label Lanreotid, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidModerat

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (label Lanreotid, Peringatan dan perhatian)

  • Linagliptinpenghambat DPP-4Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Liotironinhormon tiroidModerat

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (label Lanreotid, Peringatan dan perhatian)

  • Liraglutidagonis reseptor GLP-1Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • MetforminbiguanidModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Metoprololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Metoprolol dan hidroklorotiazidpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • MiglitolantidiabetesModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Nadololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • NateglinidmeglitinidModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Nebivololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Pindololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • PioglitazontiazolidindionModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Pioglitazon dan metformintiazolidindionModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Propiltiourasilobat antitiroidModerat

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (label Lanreotid, Peringatan dan perhatian)

  • Propranololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • RepaglinidmeglitinidModerat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Semaglutidagonis reseptor GLP-1Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • SiklosporinimunosupresanModerat

    Cyclosporine : Lanreotide Injection may decrease the absorption of cyclosporine. (label Lanreotid, Interaksi obat)

  • Sitagliptinpenghambat DPP-4Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

  • Sotalolpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Teriparatidhormon tiroidModerat

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (label Lanreotid, Peringatan dan perhatian)

  • Tiamazolobat antitiroidModerat

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (label Lanreotid, Peringatan dan perhatian)

  • Timololpenyekat betaModerat

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (label Lanreotid, Interaksi obat)

  • Tirzepatidagonis reseptor GLP-1Moderat

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

Periksa Lanreotid terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.